LGND - Johnson & Johnson posts Q4 beat as pharma and MedTech outperform
2024-01-23 07:08:06 ET
More on Genmab, Johnson & Johnson, etc.
- Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?
- Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition
- Genmab: 3 Trends To Track For A Strong 2024 And Beyond
- Johnson & Johnson beats top and bottom line estimates; reaffirms FY24 outlook
- CAR-T therapies to get boxed warning on blood cancer risk